IUPAC/Chemical Name
Butanoic acid, 4-oxo-4-((4-oxo-4-((phenylmethoxy)amino)-1,1-bis(3-oxo-3-((phenylmethoxy)amino)propyl)butyl)amino)-
InChi Key
BFVFOJHFCINJSJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C35H42N4O9/c40-30(16-17-34(44)45)36-35(21-18-31(41)37-46-24-27-10-4-1-5-11-27,22-19-32(42)38-47-25-28-12-6-2-7-13-28)23-20-33(43)39-48-26-29-14-8-3-9-15-29/h1-15H,16-26H2,(H,36,40)(H,37,41)(H,38,42)(H,39,43)(H,44,45)
SMILES Code
O=C(O)CCC(NC(CCC(NOCC1=CC=CC=C1)=O)(CCC(NOCC2=CC=CC=C2)=O)CCC(NOCC3=CC=CC=C3)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
662.74
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. Clin Cancer Res. 1999 Oct;5(10 Suppl):2994s-3000s. PMID: 10541333.
2: Safavy A, Khazaeli MB, Mayo MS, Buchsbaum DJ. Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin. Cancer Biother Radiopharm. 1997 Dec;12(6):375-84. doi: 10.1089/cbr.1997.12.375. PMID: 10851491.
3: Safavy A, Buchsbaum DJ, Khazaeli MB. Synthesis of N-[tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic acid, trisuccin. Hydroxamic acid derivatives as a new class of bifunctional chelating agents. Bioconjug Chem. 1993 May-Jun;4(3):194-8. doi: 10.1021/bc00021a002. PMID: 8324008.
4: Safavy A, Sanders A, Qin H, Buchsbaum DJ. Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol. Bioconjug Chem. 1997 Sep-Oct;8(5):766-71. doi: 10.1021/bc970127m. PMID: 9327144.
5: Safavy A, Khazaeli MB, Qin H, Buchsbaum DJ. Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer. 1997 Dec 15;80(12 Suppl):2354-9. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2354::aid-cncr4>3.3.co;2-j. PMID: 9406683.
6: Liu G, Hnatowich DJ. Labeling biomolecules with radiorhenium: a review of the bifunctional chelators. Anticancer Agents Med Chem. 2007 May;7(3):367-77. doi: 10.2174/187152007780618144. PMID: 17504162; PMCID: PMC1949414.
7: Safavy A, Khazaeli MB, Kirk M, Coward L, Buchsbaum DJ. Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group- specific conjugation at two different loci. Bioconjug Chem. 1999 Jan- Feb;10(1):18-23. doi: 10.1021/bc980045d. PMID: 9893959.
